Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Brkr - You Need To See This

Bruker Signals Growth Pivot as Semiconductor and Overseas Orders Gain Steam

Bruker (NASDAQ:BRKR) is seeing stronger order momentum across several end markets, with semiconductor metrology, non-U.S. academic and government customers, and parts of its diagnostics business helping offset continued weakness in U.S. academic funding, a company representative said at a Jefferies

Bruker's Big Cost Cuts May Not Be Enough To Offset Margin Pain

Bruker's Big Cost Cuts May Not Be Enough To Offset Margin Pain

Bruker Corporation (NASDAQ:BRKR) reported its third-quarter earnings on Monday, beating Wall Street expectations, despite a decline in profit and revenue compared to the same period last year.

These Analysts Slash Their Forecasts On Bruker After Weaker-Than-Expected Q2 Results

These Analysts Slash Their Forecasts On Bruker After Weaker-Than-Expected Q2 Results

Bruker Corporation (NASDAQ:BRKR) reported worse-than-expected second-quarter financial results and cut its FY25 guidance on Monday.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Agilent Technologies Stock: Is A Outperforming the Healthcare Sector?

Agilent Technologies has lagged the healthcare sector over the past three months, but analysts are optimistic about the stock’s prospects.

3 Stocks With MAJOR Growth Potential

Considering the recent robust economic indicators and growing optimism, I think fundamentally strong growth stocks América Móvil (AMX), Astellas Pharma (ALPMY), and Bruker (BRKR) could be ideal investments. Continue reading.

3 'A' POWR Rated Medical Stocks to Buy

The growing adoption of automated medical platforms and rising government initiatives should bode well for the medical industry. Therefore, fundamentally strong medical stocks Agilent Technologies (A), Bruker (BRKR), and Semler Scientific (SMLR), which are A (Strong Buy) rated in our proprietary rating system, might be solid buys. Read on.

3 Medical Stocks for Steady Income

As the demand for healthcare solutions continues to rise, the medical industry is undergoing remarkable growth. With their solid fundamentals and reliable revenue streams, Cardinal Health (CAH), Bruker Corp. (BRKR), and Semler Scientific (SMLR) could present an opportunity to garner stable returns. Learn more….

inkl

Read news from The Economist, FT, and more,
with one subscription

Bruker Corporation (BRKR) Is Poised for Huge Growth

Bruker Corporation (BRKR) Is Poised for Huge Growth

The healthcare industry enjoys an inelastic demand and is well-positioned to witness resilience amid soaring health awareness and technological advancements. Healthcare stock Bruker Corporation (BRKR) is poised for huge growth in the foreseeable future. Hence, this stock could be a solid buy now. Read on….

3 Healthy Looking Stocks to Own This Week

3 Healthy Looking Stocks to Own This Week

The healthcare industry thrived during the pandemic and is well-positioned to remain buoyed amid rising healthcare spending and technological advancements. Given this backdrop, healthcare stocks Agilent Technologies (A), Bruker Corporation (BRKR), and Semler Scientific (SMLR) could be ideal buys. Read on.

Bruker: Q1 Earnings Insights

Bruker: Q1 Earnings Insights

Bruker (NASDAQ:BRKR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

2 Mid-Cap Stocks Down 25% to Buy Now

2 Mid-Cap Stocks Down 25% to Buy Now

Investor concerns over rising inflation, the possibility of aggressive interest rate increases, and rising COVID-19 cases in China caused major benchmark indexes to tumble last week. So, given the current market volatility and unpredictable macroeconomic environment, we think investors should consider investing in fundamentally sound mid-cap stocks Bruker (BRKR) and…

Bruker: Dividend Insights

Bruker: Dividend Insights

Sunday marks the last chance for investors to receive the next dividend payout from Bruker (NASDAQ:BRKR).

Bruker Posts 11% Organic Growth In Q4 Sales, Issues FY22 Outlook

Bruker Posts 11% Organic Growth In Q4 Sales, Issues FY22 Outlook

Bruker Corp's (NASDAQ: BRKR) Q4 revenues

1

People

Kritika SarmahHer

Steve Reitmeister

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Conference Board

Cardinal Health Inc

Astellas Pharma Inc

Agilent Technologies Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

392,216 stories

142,998 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play